Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
NCT01540461
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
17
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Brivanib
Sponsor
Bristol-Myers Squibb